Interval Cancer Rate and Diagnostic Performance of Fecal Immunochemical Test According to Family History of Colorectal Cancer

被引:1
|
作者
Jung, Yoon Suk [1 ]
Lee, Jinhee [2 ]
Lee, Hye Ah [3 ]
Moon, Chang Mo [4 ,5 ]
机构
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Gastroenterol,Sch Med, Seoul 03181, South Korea
[2] Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon 16499, South Korea
[3] Ewha Womans Univ, Clin Trial Ctr, Mokdong Hosp, Seoul 07985, South Korea
[4] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul 07985, South Korea
[5] Ewha Womans Univ, Coll Med, Inflammat Canc Microenvironm Res Ctr, Seoul 07985, South Korea
基金
新加坡国家研究基金会;
关键词
family history of colorectal cancer; fecal immunochemical test; colorectal cancer; RISK; INDIVIDUALS; COLONOSCOPY;
D O I
10.3390/jcm9103302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The potential role of the fecal immunochemical test (FIT) in individuals with a family history of colorectal cancer (CRC) remains unclear. We assessed interval cancer rate (ICR) after the FIT and FIT diagnostic performance according to family history of CRC. Methods: Using the Korean National Cancer Screening Program Database, we collected data on subjects who underwent the FIT between 2009 and 2011. The interval cancer rate (ICR) was defined as the number of subjects diagnosed with CRC within 1 year after the FIT per 1000 subjects with negative FIT results. Results: Of 5,643,438 subjects, 224,178 (3.97%) had a family history of CRC. FIT positivity rate (6.4% vs. 5.9%; adjusted relative risk (aRR) 1.11; 95% confidence interval (CI) 1.09-1.13) and ICR (1.4 vs. 1.1; aRR 1.43 (95% CI 1.27-1.60)) were higher in these subjects than in those with no such history. These results were the same regardless of whether subjects had undergone colonoscopy within the last 5 years before the FIT. However, the diagnostic performance of the FIT for CRC, as measured using the area under the operating characteristic curve, was similar between subjects without a family history and those with one (85.5% and 84.6%, respectively; p = 0.259). Conclusion: the FIT was 1.4 times more likely to miss CRC in subjects with a family history than in those without (aRR 1.43 for ICR), although its diagnostic performance was similar between the two groups. Our results suggest that for individuals with a family history of CRC, colonoscopy should be preferred over FIT for both screening and surveillance.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [41] Advantage of immunochemical fecal occult blood test in screening for colorectal cancer
    Launoy, G
    Berchi, C
    BULLETIN DU CANCER, 2005, 92 (10) : 885 - 890
  • [42] Colorectal cancer risk after removal of polyps in fecal immunochemical test based screening
    van Toledo, D. E. F. W. M.
    IJspeert, J. E. G.
    Spaander, M. C. W.
    Nagtegaal, I. D.
    van Leerdam, M. E.
    Lansdorp-Vogelaar, I.
    Dekker, E.
    ECLINICALMEDICINE, 2023, 61
  • [43] Faecal immunochemical test outside colorectal cancer screening?
    Pin-Vieito, Noel
    Puga, Manuel
    Fernandez-de-Castro, Daniel
    Cubiella, Joaquin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (38) : 6415 - 6429
  • [44] Fecal immunochemical test accuracy in familial risk colorectal cancer screening
    Castro, Ines
    Cubiella, Joaquin
    Rivera, Concepcion
    Gonzalez-Mao, Carmen
    Vega, Pablo
    Soto, Santiago
    Hernandez, Vicent
    Iglesias, Felipe
    Teresa Alves, Maria
    Bujanda, Luis
    Fernandez-Seara, Javier
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (02) : 367 - 375
  • [45] The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design
    P. H. A. Wisse
    W. de Klaver
    F. van Wifferen
    L. Meiqari
    M. Bierkens
    M. J. E. Greuter
    B. Carvalho
    M. E. van Leerdam
    M. C. W. Spaander
    E. Dekker
    V. M. H. Coupé
    M. de Wit
    G. A. Meijer
    BMC Cancer, 22
  • [46] Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer
    Baldacchini, Flavia
    Bucchi, Lauro
    Giuliani, Orietta
    Mancini, Silvia
    Ravaioli, Alessandra
    Vattiato, Rosa
    Rossi, Paolo Giorgi
    Campari, Cinzia
    Canuti, Debora
    Di Felice, Enza
    Mezzetti, Francesca
    de Bianchi, Priscilla Sassoli
    Ferretti, Stefano
    Falcini, Fabio
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (11) : 2361 - 2369
  • [47] Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence
    Laven-Law, Geraldine
    Symonds, Erin L.
    Winter, Jean M.
    Chen, Gang
    Flight, Ingrid H.
    Hughes-Barton, Donna
    Wilson, Carlene J.
    Young, Graeme P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (07) : 1267 - 1276
  • [48] Population Screening for Colorectal Cancer Means Getting FIT: The Past, Present, and Future of Colorectal Cancer Screening Using the Fecal Immunochemical Test for Hemoglobin (FIT)
    Allison, James E.
    Fraser, Callum G.
    Halloran, Stephen P.
    Young, Graeme P.
    GUT AND LIVER, 2014, 8 (02) : 117 - 130
  • [49] Characteristics of Advanced Colorectal Cancer Detected by Fecal Immunochemical Test Screening in Participants with a Negative Result the Previous Year
    Hasegawa, Ryosuke
    Yashima, Kazuo
    Ikebuchi, Yuichiro
    Sasaki, Shuji
    Yoshida, Akira
    Kawaguchi, Koichiro
    Isomoto, Hajime
    YONAGO ACTA MEDICA, 2020, 63 (01) : 63 - 69
  • [50] Quality Improvement of Sample Collection Increases the Diagnostic Accuracy of Quantitative Fecal Immunochemical Test in Colorectal Cancer Screening: A Pilot Study
    Zhou, Ru-chen
    Wang, Pei-zhu
    Li, Yue-yue
    Zhang, Yan
    Ma, Ming-jun
    Meng, Fan-yi
    Liu, Chao
    Yang, Xiao-yun
    Lv, Ming
    Zuo, Xiu-li
    Li, Yan-qing
    FRONTIERS IN MEDICINE, 2021, 8